share_log

Bluebird Bio (NASDAQ:BLUE) Shares Up 5.5% on Analyst Upgrade

Bluebird Bio (NASDAQ:BLUE) Shares Up 5.5% on Analyst Upgrade

分析师上调后,蓝鸟生物(纳斯达克股票代码:BLUE)股价上涨5.5%
Defense World ·  2023/01/25 17:01

Shares of bluebird bio, Inc. (NASDAQ:BLUE – Get Rating) were up 5.5% during mid-day trading on Tuesday after Morgan Stanley raised their price target on the stock from $3.00 to $4.00. Morgan Stanley currently has an underweight rating on the stock. bluebird bio traded as high as $6.60 and last traded at $6.53. Approximately 3,046,105 shares changed hands during trading, a decline of 37% from the average daily volume of 4,807,327 shares. The stock had previously closed at $6.19.

在摩根士丹利将蓝鸟生物股份有限公司(纳斯达克代码:Blue-Get)的目标价从3.00美元上调至4.00美元后,该公司股价周二午盘上涨5.5%。摩根士丹利目前对该股的评级为减持。蓝鸟生物的交易价格曾高达6.60美元,最新报6.53美元。约3,046,105股股票在交易中易手,较4,807,327股的日均成交量下降了37%。该股此前收盘价为6.19美元。

Other equities analysts have also recently issued reports about the stock. StockNews.com started coverage on shares of bluebird bio in a research report on Wednesday, October 12th. They set a "sell" rating for the company. Royal Bank of Canada decreased their price target on shares of bluebird bio to $8.00 and set a "sector perform" rating for the company in a research report on Tuesday, November 8th. Finally, SVB Leerink decreased their price target on shares of bluebird bio from $9.00 to $8.00 and set a "market perform" rating for the company in a research report on Monday. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $6.75.

其他股票分析师最近也发布了有关该股的报告。股票新闻网站在10月12日星期三的一份研究报告中开始对蓝鸟生物的股票进行报道。他们为该公司设定了“卖出”评级。11月8日,加拿大皇家银行在一份周二的研究报告中将蓝鸟生物的目标股价下调至8.00美元,并为该公司设定了“行业表现”评级。最后,SVB Leerink将蓝鸟生物股票的目标价从9.00美元下调至8.00美元,并在周一的一份研究报告中为该公司设定了“市场表现”评级。三位股票研究分析师对该股的评级为卖出,六位分析师给出了持有评级,一位分析师给出了该公司股票的买入评级。根据MarketBeat.com的数据,该股的平均评级为持有,平均目标价为6.75美元。

Get
到达
bluebird bio
蓝鸟传记
alerts:
警报:

Insider Transactions at bluebird bio

蓝鸟生物的内幕交易

In other news, Director Nick Leschly sold 4,290 shares of the stock in a transaction on Wednesday, January 11th. The shares were sold at an average price of $7.80, for a total transaction of $33,462.00. Following the completion of the sale, the director now directly owns 280,149 shares in the company, valued at $2,185,162.20. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders sold a total of 9,506 shares of company stock worth $72,088 over the last three months. 2.20% of the stock is owned by company insiders.

其他新闻方面,董事尼克·莱施利在1月11日星期三的一次交易中出售了4,290股该公司股票。这些股票以7.80美元的平均价格出售,总成交额为33,462.00美元。出售完成后,董事现在直接拥有该公司280,149股,价值2,185,162.20美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可在这个环节。过去三个月,内部人士总共出售了9,506股公司股票,价值72,088美元。2.20%的股份由公司内部人士持有。

Institutional Investors Weigh In On bluebird bio

机构投资者参与蓝鸟生物

A number of large investors have recently bought and sold shares of the stock. Inspire Investing LLC grew its holdings in bluebird bio by 3.6% in the second quarter. Inspire Investing LLC now owns 50,497 shares of the biotechnology company's stock worth $209,000 after purchasing an additional 1,773 shares during the period. Raymond James Financial Services Advisors Inc. grew its holdings in bluebird bio by 6.4% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 35,817 shares of the biotechnology company's stock worth $227,000 after purchasing an additional 2,156 shares during the period. Captrust Financial Advisors grew its holdings in bluebird bio by 22.5% in the third quarter. Captrust Financial Advisors now owns 14,679 shares of the biotechnology company's stock worth $93,000 after purchasing an additional 2,700 shares during the period. Metropolitan Life Insurance Co NY grew its holdings in bluebird bio by 142.4% in the third quarter. Metropolitan Life Insurance Co NY now owns 4,671 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 2,744 shares during the period. Finally, US Bancorp DE grew its holdings in bluebird bio by 82.9% in the first quarter. US Bancorp DE now owns 8,486 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 3,847 shares during the period. 79.01% of the stock is currently owned by institutional investors and hedge funds.
一些大型投资者最近买卖了该股的股票。第二季度,Inspire Investment LLC对蓝鸟生物的持股增加了3.6%。Inspire Investment LLC现在拥有这家生物技术公司50,497股股票,价值20.9万美元,在此期间又购买了1,773股。雷蒙德·詹姆斯金融服务顾问公司(Raymond James Financial Services Advisors Inc.)在第三季度增持了蓝鸟生物6.4%的股份。雷蒙德·詹姆斯金融服务顾问公司(Raymond James Financial Services Advisors Inc.)目前持有这家生物技术公司35,817股股票,价值22.7万美元,在此期间又购买了2,156股。CapTrust Financial Advisors在第三季度增持了蓝鸟生物22.5%的股份。CapTrust Financial Advisors目前持有这家生物技术公司14,679股股票,价值93,000美元,在此期间又购买了2,700股。纽约大都会人寿保险公司第三季度对蓝鸟生物的持有量增长了142.4%。纽约大都会人寿保险公司在此期间又购买了2744股,现在拥有4671股生物技术公司的股票,价值3万美元。最后,US Bancorp DE在第一季度增持了82.9%的蓝鸟生物。US Bancorp DE现在持有这家生物技术公司8486股股票,价值4.1万美元,在此期间又购买了3847股。79.01%的股票目前由机构投资者和对冲基金持有。

bluebird bio Price Performance

蓝鸟生物性价比

The firm has a market capitalization of $541.49 million, a price-to-earnings ratio of -1.07 and a beta of 0.99. The business's fifty day simple moving average is $7.40 and its 200 day simple moving average is $6.52.

该公司市值为5.4149亿美元,市盈率为-1.07倍,贝塔系数为0.99。该业务的50日简单移动均线切入位为7.40美元,200日简单移动均线切入位为6.52美元。

bluebird bio (NASDAQ:BLUE – Get Rating) last posted its quarterly earnings results on Monday, November 7th. The biotechnology company reported ($0.92) EPS for the quarter, topping analysts' consensus estimates of ($1.28) by $0.36. The business had revenue of $0.07 million during the quarter, compared to analysts' expectations of $2.25 million. bluebird bio had a negative net margin of 8,828.28% and a negative return on equity of 173.58%. Equities research analysts expect that bluebird bio, Inc. will post -4.36 earnings per share for the current fiscal year.

青鸟生物(纳斯达克:Blue-Get Rating)最近一次公布季度收益是在11月7日(星期一)。这家生物技术公司公布了该季度每股收益(0.92美元),比分析师普遍预期的(1.28美元)高出0.36美元。该业务本季度营收为70万美元,高于分析师预期的225万美元。蓝鸟生物的净利润率为负8828.28%,净资产回报率为负173.58%。股票研究分析师预计,蓝鸟生物公司本财年每股收益将达到4.36美元。

About bluebird bio

关于蓝鸟传记

(Get Rating)

(获取评级)

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.

蓝鸟生物公司是一家生物技术公司,研究、开发和商业化针对严重遗传病的变革性基因疗法。其用于治疗严重遗传性疾病的候选产品包括用于治疗输血依赖型β-地中海贫血的贝替贝吉基因Autotemcel;用于治疗镰状细胞病(SCD)的lovotieglogene autemcel;以及用于治疗大脑肾上腺脑白质营养不良的伊利伐多烯Autotemcel。

Featured Articles

专题文章

  • Get a free copy of the StockNews.com research report on bluebird bio (BLUE)
  • High-Yield, Deep-Value Verizon Puts In A Bottom
  • Should You Bet Against The Nasdaq 100 With This Inverse ETF?
  • Can Coty Stock Emerge in 2023 With Upside
  • Insiders Buy Archer Aviation, Is This Stock About To Take Off?
  • Intuit Is About To Make a Move, But Which Way?
  • 免费获取StockNews.com关于蓝鸟生物的研究报告(蓝色)
  • 高收益、高价值的Verizon陷入谷底
  • 你应该用这只反向ETF做空纳斯达克100指数吗?
  • 科蒂股票能否在2023年出现上行
  • 业内人士买入阿彻航空,这只股票要起飞了吗?
  • Intuit即将采取行动,但走哪条路呢?

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

获得蓝鸟生物日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对蓝鸟生物和相关公司的最新新闻和分析师评级的每日简明摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发